Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Horizon Therapeutics (NQ: HZNP ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Oct 5, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Horizon Therapeutics < Previous 1 2 3 4 5 6 7 8 Next > Horizon Therapeutics plc Named a Best Company for Multicultural Women July 25, 2022 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics plc Announces Inaugural #RAREis Global Advocate Grant Recipients July 21, 2022 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics plc Announces Wanda Durant Has Joined Olympian Gail Devers to Raise Awareness of Thyroid Eye Disease Among Graves’ Disease Community July 11, 2022 From Horizon Therapeutics plc Via Business Wire FDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy July 08, 2022 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics plc to Release Second-Quarter 2022 Financial Results and Host Webcast on Aug. 3, 2022 July 07, 2022 From Horizon Therapeutics plc Via Business Wire New Analysis Finds UPLIZNA® (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD) June 24, 2022 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics plc Submits Regulatory Filing for UPLIZNA® (inebilizumab) in Brazil June 15, 2022 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics plc Named One of the Fortune Best Workplaces in Chicago™ June 15, 2022 From Horizon Therapeutics plc Via Business Wire Analysis of Pooled Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials Reinforces Safety Profile in People with Thyroid Eye Disease (TED) June 11, 2022 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics plc Named a Top Company for Executive Women June 09, 2022 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics plc to Present at the Goldman Sachs 43rd Annual Global Health Care Conference June 06, 2022 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics plc to Highlight Data and Education on Thyroid Eye Disease (TED) at the Endocrine Society (ENDO) 2022 Annual Conference June 02, 2022 From Horizon Therapeutics plc Via Business Wire Data Presented from the MIRROR Randomized Controlled Trial Demonstrate KRYSTEXXA® (pegloticase injection) Plus Methotrexate Resulted in Significant Improvement in Efficacy and Safety (Infusion Reactions) Compared to KRYSTEXXA Monotherapy June 01, 2022 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics plc Wins 2022 International CSR Excellence Award for #RAREis Adoption Fund May 31, 2022 From Horizon Therapeutics plc Via Business Wire Analysis from the Phase 3 N-MOmentum Study Demonstrates the Effectiveness of UPLIZNA® (inebilizumab-cdon) Among Neuromyelitis Optica Spectrum Disorder Patients with Genetic Variations May 31, 2022 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics plc to Present MIRROR Randomized Controlled Trial Primary Endpoint Data at The EULAR 2022 European Congress of Rheumatology May 24, 2022 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (HZN-7734) for the Treatment of Alopecia Areata May 17, 2022 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics plc Ranked Second in Overall Corporate Reputation in U.S. PatientView Survey of Patient Groups May 16, 2022 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics plc Announces Dara Mann as a Healthcare Businesswomen’s Association 2022 Rising Star May 11, 2022 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics plc Launches Letter-Writing Campaign to Empower Those Living with Thyroid Eye Disease (TED) to Confront the Condition Head On May 11, 2022 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics and Chicago Sky Announce Multi-Year Partnership May 09, 2022 From Horizon Therapeutics Via Business Wire Horizon Therapeutics plc Reports First-Quarter 2022 Financial Results May 04, 2022 From Horizon Therapeutics plc Via Business Wire Topline Data for Dazodalibep (HZN-4920) Meets Primary Endpoint in Rheumatoid Arthritis May 03, 2022 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics plc Launches #RAREis Global Advocate Grant Program to Support the Rare Disease Community May 02, 2022 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) May 02, 2022 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics plc Among Top Companies for Overall Corporate Reputation in 2021 Global PatientView Survey of Patient Groups Worldwide April 27, 2022 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics and Massachusetts Institute of Technology (MIT) Solve Announce Second Annual Horizon Prize to Inspire Solutions that Improve the Quality of Life for the Global Rare Disease Community April 19, 2022 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics plc to Release First-Quarter 2022 Financial Results and Host Webcast on May 4, 2022 April 14, 2022 From Horizon Therapeutics plc Via Business Wire Horizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For® April 11, 2022 From Horizon Therapeutics plc Via Business Wire New Analysis Finds UPLIZNA® (inebilizumab-cdon) Effective for People with Newly-Presenting Neuromyelitis Optica Spectrum Disorder (NMOSD) March 31, 2022 From Horizon Therapeutics plc Via Business Wire < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.